compound semaglutide hims This week, pharmaceutical startup Hims & Hers Health launched an initiative to offer GLP The FDA announced plans to

This may improve overall metabolic health, enhance drug efficacy, and reduce potential side effects

Here are the evidence-based first-line treatments, ranked by effectiveness and ease of access

How to dispose of Ozempic Ozempic comes with Novofine pen needles

[1] Body weight and composition can influence the volume of distribution for GLP-1 medications, potentially affecting elimination kinetics

The industry is racing to figure out the effects of GLP-1 agonists on different conditions and populations and to test for secondary indications to treat cardiovascular diseases and liver disorders

A study by Mass Eye and Ear (which was published in JAMA Ophthalmology) found that those on semaglutide were four times more likely to develop NAION (17 of 200 diabetes patients) and seven times more likely to develop NAION if they were also obese or overweight (20 of 361 overweight or obese patients)